US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
pharma · Solid Tumors · RAS Mutation · KTTA
Pasithea Therapeutics
Pasithea Therapeutics drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Miami Beach, USA HQ
2020 Founded
11 Employees
Public company Type
KTTA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Miami Beach, USA
- Founded
- 2020
- Employees
- 11
- Programs
- 3
- Drugs
- 6
- Patents
- 0
Pasithea Therapeutics pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Pasithea Therapeutics drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Pasithea Therapeutics in public FDA and regional records.
-
Development asset linked to Pasithea Therapeutics in public FDA and regional records.
-
Development asset linked to Pasithea Therapeutics in public FDA and regional records.
-
Development asset linked to Pasithea Therapeutics in public FDA and regional records.
-
Development asset linked to Pasithea Therapeutics in public FDA and regional records.